Independent Advisor Alliance Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Independent Advisor Alliance purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,777 shares of the medical equipment provider’s stock, valued at approximately $444,000.

Several other institutional investors and hedge funds have also recently modified their holdings of HOLX. Fieldpoint Private Securities LLC boosted its position in shares of Hologic by 61.4% during the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. Hudock Inc. boosted its position in shares of Hologic by 1,825.0% during the 1st quarter. Hudock Inc. now owns 385 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 365 shares during the last quarter. FinTrust Capital Advisors LLC acquired a new position in shares of Hologic during the 1st quarter valued at about $45,000. Quent Capital LLC acquired a new position in shares of Hologic during the 4th quarter valued at about $51,000. Finally, Rosenberg Matthew Hamilton acquired a new position in shares of Hologic during the 1st quarter valued at about $55,000. Institutional investors and hedge funds own 92.70% of the company’s stock.

Hologic Stock Up 0.3 %

Shares of NASDAQ:HOLX opened at $71.40 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. The firm has a market capitalization of $17.83 billion, a PE ratio of 12.04, a price-to-earnings-growth ratio of 0.81 and a beta of 1.05. The firm’s 50-day moving average is $71.14 and its two-hundred day moving average is $72.79. Hologic, Inc. has a 1 year low of $66.58 and a 1 year high of $81.04.

Hologic (NASDAQ:HOLXGet Rating) last released its earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.26. Hologic had a net margin of 28.93% and a return on equity of 37.48%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $896.71 million. During the same period in the prior year, the firm earned $1.33 earnings per share. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 5.82 EPS for the current year.

Insider Buying and Selling

In related news, insider Jan Verstreken sold 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $78.80, for a total transaction of $512,200.00. Following the sale, the insider now directly owns 64,191 shares in the company, valued at $5,058,250.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on HOLX shares. Citigroup decreased their target price on shares of Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. BTIG Research cut shares of Hologic from a “buy” rating to a “neutral” rating in a research report on Monday, July 18th. Morgan Stanley decreased their target price on shares of Hologic from $72.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 28th. UBS Group started coverage on shares of Hologic in a research report on Wednesday, July 20th. They issued a “neutral” rating and a $73.00 target price on the stock. Finally, Wells Fargo & Company cut shares of Hologic from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $90.00 to $75.00 in a research report on Monday, April 25th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $76.71.

Hologic Profile

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Recommended Stories

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.